METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung C
Go back to METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung C| (NASDAQ: NVCR) | Delayed: 13.69 -0.59 (4.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $14.28 | 52 Week High | $28.95 | |||
| Open | $14.33 | 52 Week Low | $5.95 | |||
| Day High | $14.51 | P/E | N/A | |||
| Day Low | $13.56 | EPS | $0.00 | |||
| Volume | 892,780 | |||||
